CTOs on the Move

Lundbeck

www.lundbeck.com

 
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company`s products are targeted at disease areas such as depression, schizophrenia, Parkinson`s disease and Alzheimer`s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.lundbeck.com
  • Six Parkway North Suite 400
    Deerfield, IL USA 60015
  • Phone: 847.282.1000

Executives

Name Title Contact Details

Similar Companies

Chartiers Center

Chartiers’ primary focus is the integration of physical health and mental health wellness to enhance the quality of life for all people with behavioral or intellectual/ and developmental disabilities. Chartiers operates programs for adults with inte...

hope pharma inc

hope pharma inc is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Olema Pharmaceuticals

Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.

Net-Rx

Net-Rx is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.